Expert Review of Vaccines最新文献_第7页

Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response. 尼帕疫苗开发和流行病防范和应对许可方面的进展和挑战。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI: 10.1080/14760584.2025.2476523

Sol Kim, Hyolim Kang, Laura Skrip, Sushant Sahastrabuddhe, Ausraful Islam, Sung-Mok Jung, Juan F Vesga, Akira Endo, W John Edmunds, Kaja Abbas

{"title":"Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response.","authors":"Sol Kim, Hyolim Kang, Laura Skrip, Sushant Sahastrabuddhe, Ausraful Islam, Sung-Mok Jung, Juan F Vesga, Akira Endo, W John Edmunds, Kaja Abbas","doi":"10.1080/14760584.2025.2476523","DOIUrl":"10.1080/14760584.2025.2476523","url":null,"abstract":"Introduction: Nipah virus is a high-consequence pathogen that causes sporadic outbreaks with high mortality, and there are currently no vaccines or therapeutics available for Nipah. Vaccine development against Nipah faces challenges due to its current epidemiology with limited outbreak sizes, which impedes the feasibility of conducting vaccine efficacy trials focused on disease endpoints.Areas covered: We review the progress of Nipah vaccine candidates in human clinical trials and highlight the challenges in evaluating the vaccine efficacy due to the sporadic nature of Nipah outbreaks, given the epidemic potential of Nipah virus and its implications for pandemic preparedness. We examine the alternative regulatory pathways, including the US FDA's Animal Rule and EMA's conditional marketing authorization, which permit vaccine approval based on surrogate markers rather than efficacy data from the large-scale Phase-3 efficacy trials. The need for standardized immune surrogate markers is emphasized, alongside calls for international collaboration to develop such endpoints and manage stockpile strategies.Expert opinion: We recommend alignment among vaccine developers, regulators, and global health stakeholders to incentivize Nipah vaccine development and approval through alternative regulatory pathways, as well as ensuring epidemic preparedness via strategic vaccine stockpiling and response through targeted deployment strategies.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"183-193"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model. 使用马尔可夫决策树模型估计哥伦比亚适应疫苗接种战略的潜在公共卫生和经济影响。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-30 DOI: 10.1080/14760584.2025.2485251

Jair Alberto Arciniegas, Juan Manuel Reyes, Carlos Fernando Mendoza, Iustina Chirila, Moe Hein Kyaw, Omar Escobar, Jorge Enrique La Rotta, Ben Yarnoff

{"title":"Estimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model.","authors":"Jair Alberto Arciniegas, Juan Manuel Reyes, Carlos Fernando Mendoza, Iustina Chirila, Moe Hein Kyaw, Omar Escobar, Jorge Enrique La Rotta, Ben Yarnoff","doi":"10.1080/14760584.2025.2485251","DOIUrl":"10.1080/14760584.2025.2485251","url":null,"abstract":"Background: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. This study evaluated the impact of various vaccination strategies with an adapted vaccine in Colombia.Research design and methods: Using a previously published combined Markov-decision tree model adapted for the Colombia context, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality of life inputs derived from the published literature and national surveillance data. Scenario and sensitivity analyses were conducted to assess uncertainty.Results: Compared to no vaccination, the vaccination strategy targeting older adults aged ≥65 years and the high-risk population was estimated to prevent 306,460 symptomatic cases, 5,200 hospitalizations, 3,381 deaths, and 39,454 lost QALYs, translating to total direct and societal cost savings of USD 70,840,305 and USD 128,918,995, respectively. These gains were further increased by expanding vaccination to additional age groups. Results were most sensitive to parameters for the attack rate and duration of protection.Conclusions: Implementing vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits in Colombia.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"242-251"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Control measures for neglected tropical diseases: vaccine updates. 被忽视的热带病控制措施：疫苗更新。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-14 DOI: 10.1080/14760584.2025.2517712

Vivek P Chavda, Suneetha Vuppu, Toshika Mishra, Nikita Sharma, Sathvika Kamaraj, Shatakshi Mishra, Bhumi Sureshbhai, John Matsoukas, Vasso Apostolopoulos

{"title":"Control measures for neglected tropical diseases: vaccine updates.","authors":"Vivek P Chavda, Suneetha Vuppu, Toshika Mishra, Nikita Sharma, Sathvika Kamaraj, Shatakshi Mishra, Bhumi Sureshbhai, John Matsoukas, Vasso Apostolopoulos","doi":"10.1080/14760584.2025.2517712","DOIUrl":"10.1080/14760584.2025.2517712","url":null,"abstract":"Introduction: Infectious diseases like neglected tropical diseases (NTDs) have seen a rapid surge in recent times, threatening public health. These diseases impose a significant global health burden, affecting individuals, particularly in tropical locations characterized by low-income populations. The comprehensive compilation of NTDs includes an array of bacterial, viral, and parasitic infections. The prioritization of 20-NTD action plans in 2020 was undertaken by the WHO to acknowledge their importance. Infections such as leishmaniasis, schistosomiasis, and human African trypanosomiasis exhibit high rates of mortality. This highlights the pressing need for collaborative initiatives aimed at addressing these diseases and minimizing their detrimental impact on susceptible populations.Areas covered: The etiology, types of NTDs, and management strategies, particularly vaccinations are discussed. The limitations of the available vaccines and the scope of development of novel formulations are also covered.Expert opinion: The emergence of vaccines for NTDs poses significant challenges, mostly arising from the complex developmental phases of diverse diseases, inadequate resources for research, minimal involvement from the pharmaceutical industry, and the wide spectrum of infections, impeding vaccine development. Advancements in technology have improved vaccine quality, which could lead to the development of personalized vaccines tailored to individual susceptibility to specific NTD pathogens.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"535-555"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis. 2003年至2023年儿童流感减毒活疫苗（LAIV）和灭活疫苗（iv）的实际有效性：系统文献综述和网络荟萃分析

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-30 DOI: 10.1080/14760584.2025.2536087

Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus

{"title":"Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis.","authors":"Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus","doi":"10.1080/14760584.2025.2536087","DOIUrl":"10.1080/14760584.2025.2536087","url":null,"abstract":"Introduction: Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NMA) estimated absolute VE (aVE) and relative VE (rVE) of LAIV and IIV in children/adolescents from initial LAIV approval in 2003.Methods: Northern Hemisphere studies (2003-2023) with children ≤19 yrs were included. A modified Newcastle-Ottawa Scale assessed risk-of-bias. REMA estimated aVE and three-node NMA (LAIV-IIV-unvaccinated) estimated rVE over three periods: 2003-04 to 2008-09 (pre-2009 A(H1N1) pandemic); 2010-11 to 2016-17 (post-2009 pandemic); 2017-18 to 2022-23 (post-LAIV strain-selection optimization).Results: One hundred and nine studies included. aVE of LAIV and IIV against any influenza was similar (~50%) in each period. Effectiveness of LAIV vs. IIV against influenza types/subtypes was comparable except (1) greater effectiveness with IIV for A(H1N1) in 2010-11 to 2016-17 (rVE -46% [95% CI: -57, -33]); (2) greater effectiveness with LAIV for influenza B in 2017-18 to 2022-23 (rVE 196% [95% CI: 73, 406]). In 2017-18 to 2022-23, effectiveness of LAIV and IIV against A(H1N1) was similar (rVE 10% [95% CI: -35, 87]).Conclusions: LAIV and IIV have demonstrated comparable effectiveness against any influenza in children.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"703-725"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward elimination of hepatitis A and B in Europe: vaccination successes, challenges, and opportunities. 在欧洲实现消除甲型和乙型肝炎：疫苗接种的成功、挑战和机遇。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-20 DOI: 10.1080/14760584.2025.2502030

Maria Buti, Paolo Bonanni, Nimzing Ladep, George Papatheodoridis, Markus Frühwein, Cary James, John W Ward, Volker Vetter, Pasquale Cacciatore, Divya Kesters, Pavitra Dewda, Pierre Van Damme

{"title":"Toward elimination of hepatitis A and B in Europe: vaccination successes, challenges, and opportunities.","authors":"Maria Buti, Paolo Bonanni, Nimzing Ladep, George Papatheodoridis, Markus Frühwein, Cary James, John W Ward, Volker Vetter, Pasquale Cacciatore, Divya Kesters, Pavitra Dewda, Pierre Van Damme","doi":"10.1080/14760584.2025.2502030","DOIUrl":"10.1080/14760584.2025.2502030","url":null,"abstract":"Introduction: Hepatitis B and hepatitis A are vaccine-preventable infections of global concern. Hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccines available in Europe are underutilized in some age groups. While most European countries implemented childhood HBV universal routine vaccination (URV), vaccination coverage among adults remains low. Low HAV vaccination coverage among high-risk populations due to variable national vaccination policies, low awareness of vaccination benefits, and other barriers, increases the risk for outbreaks.Areas covered: We discuss the awareness of hepatitis B and hepatitis A burden in different populations in Europe, vaccination recommendations, successes, challenges, and opportunities for their implementation.Expert opinion: Awareness of at-risk populations and HBV/HAV vaccination recommendations should be raised among healthcare providers and the general population to increase access to vaccination. Increasing awareness that HBV vaccination contributes to reduction in the incidence of hepatocellular carcinoma can motivate adults to get vaccinated. Adult HBV URV may be considered in Europe, as in the United States, pending cost-effectiveness assessment at national levels. HAV vaccination recommendations should be updated and expanded to all at-risk persons. National HBV/HAV targets and vaccination strategies should be actively promoted to accelerate the elimination of viral hepatitis in Europe.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"373-383"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in co-administration of adult vaccinations in the US retail pharmacy setting. 在美国零售药房设置成人疫苗共同管理的趋势。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-05 DOI: 10.1080/14760584.2025.2514517

Neha Agrawal, Alon Yehoshua, Jeffrey T Vietri, Tianyan Hu, Taryn Pond, Maria J Tort, Jingyan Yang, Verna Welch, Constantina Boikos, Sen Deng, Hao Zheng, Anchita Goswami, Manvi Sharma, Reiko Sato

{"title":"Trends in co-administration of adult vaccinations in the US retail pharmacy setting.","authors":"Neha Agrawal, Alon Yehoshua, Jeffrey T Vietri, Tianyan Hu, Taryn Pond, Maria J Tort, Jingyan Yang, Verna Welch, Constantina Boikos, Sen Deng, Hao Zheng, Anchita Goswami, Manvi Sharma, Reiko Sato","doi":"10.1080/14760584.2025.2514517","DOIUrl":"10.1080/14760584.2025.2514517","url":null,"abstract":"Background: Evidence on trends in co-administration of vaccines among adults is limited. This study assessed monthly trends in co-administration of US Advisory Committee on Immunization Practices (ACIP) recommended vaccines in the retail pharmacy setting and evaluated commonly co-administered vaccine combinations.Research design and methods: This retrospective study used Adheris Pharmacy Dataset, including adults aged ≥ 19 years who received ≥ 1 vaccine from August 2018 to December 2023. Co-administration was defined as administration of > 1 vaccine on same day. Numbers and proportions of co-administrations were assessed by month of administration and age group. Five most commonly co-administered combinations of vaccines were identified between August 2022 and December 2023.Results: Out of 161,415,432 visits with ≥ 1 vaccine administration 16,164,321 (10.0%) visits involved co-administration. Monthly co-administrations showed an upward trend from August 2018 (75,449 [11.6%]) to December 2023 (470,959 [24.0%]), with a peak in October 2023 (2,103,903 [32.6%]). Co-administration was considerably higher between September and November across the years and age groups. Influenza and COVID-19 vaccines were most commonly co-administered combination.Conclusions: Most vaccination visits (~90%) were associated with single administrations, with 10% co-administrations. An increase in vaccine co-administrations was noted in 2022 and 2023 for all age groups compared to those between 2018-2021.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"470-478"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany. 德国老年人接种二价呼吸道合胞病毒预混 F 疫苗预防呼吸道合胞病毒的成本效益。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-18 DOI: 10.1080/14760584.2024.2436183

Ahuva Averin, Bennet Huebbe, Mark Atwood, Lea J Bayer, Caroline Lade, Christof von Eiff, Reiko Sato

{"title":"Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany.","authors":"Ahuva Averin, Bennet Huebbe, Mark Atwood, Lea J Bayer, Caroline Lade, Christof von Eiff, Reiko Sato","doi":"10.1080/14760584.2024.2436183","DOIUrl":"https://doi.org/10.1080/14760584.2024.2436183","url":null,"abstract":"Introduction: Among older adults, lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) is common. We evaluated the cost-effectiveness of bivalent RSV prefusion F protein-based vaccine (RSVpreF) for prevention of RSV-LRTI among older adults in Germany.Research design and methods: A static cohort model was developed to estimate lifetime health and economic outcomes of RSV-LRTI among adults aged 60-99 years in Germany, with (vs. without) use of RSVpreF. Vaccine uptake ranged from 27% to 54%. Vaccine effectiveness was derived from trial data and was assumed to last over 3 years, with some waning, following vaccination. Base case analyses were conducted from the societal perspective (costs/benefits discounted 3% annually); sensitivity analyses also were conducted.Results: Among adults aged 60-99 years (N = 25.3 M), RSVpreF prevented 117,360 cases of hospitalized RSV-LRTI, 100,433 cases of ambulatory RSV-LRTI, and 9,298 RSV-LRTI-related deaths over a lifetime horizon. With total overall costs higher by 1.8 € billion and 49,576 quality-adjusted life-years (QALYs) gained, cost-effectiveness of RSVpreF was 36,064 €/QALY. In probabilistic sensitivity analyses, the mean cost-effectiveness ratio was 36,518 €/QALY; 925 of 1,000 replications yielded ratios <50,000 €/QALY.Conclusions: RSVpreF has the potential to greatly reduce the public health and economic burden of RSV among older adults in Germany.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"1-10"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. 18月龄时血清型特异性血清免疫球蛋白G：一项随机对照研究：接种一剂或两剂10价或13价肺炎球菌结合疫苗的初级系列，并在9月龄时接种加强剂。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/14760584.2025.2458179

Alane Izu, Eleanora Aml Mutsaerts, Courtney Olwagen, Lisa Jose, Anthonet Koen, Amit J Nana, Clare L Cutland, Shabir A Madhi

{"title":"Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study.","authors":"Alane Izu, Eleanora Aml Mutsaerts, Courtney Olwagen, Lisa Jose, Anthonet Koen, Amit J Nana, Clare L Cutland, Shabir A Madhi","doi":"10.1080/14760584.2025.2458179","DOIUrl":"10.1080/14760584.2025.2458179","url":null,"abstract":"Background: Due to high costs of pneumococcal conjugate vaccines (PCV), transitioning from a two (2 + 1) to a single dose (1 + 1) primary series with a booster should be considered. This study evaluated the immune response at 18 months of age following a 1 + 1 compared to a 2 + 1 schedule of 10-valent (PCV10) and 13-valent (PCV13) vaccines.Research design and methods: A single-center, open-label, randomized trial conducted in Soweto, South Africa, evaluated the immunogenicity of differing dosing schedule for PCV10 and PCV13. Six hundred children were randomly assigned to six study arms (1:1:1:1:1:1). Non-inferiority was concluded when the lower limit of the 96% confidence interval of the ratio of geometric mean concentrations (GMCs) of the 1 + 1 and 2 + 1 schedules was >0.5 for at least 10 and eight of the PCV13 and PCV10 serotypes, respectively.Results: GMCs in children who received the PCV13_6w + 1 and PCV13_14w + 1 schedule were non-inferior for 11 and 10 of the PCV13 serotypes, respectively, compared with the PCV13_2 + 1 arm. For PCV10, GMCs for both 1 + 1 schedules were non-inferior to a 2 + 1 schedule for nine of the PCV10 serotypes.Conclusion: Transitioning to a 1 + 1 schedule should be considered for early immunization programs.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02943902.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"121-127"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation time and usability assessment of commercially available freeze-dried respiratory syncytial virus vaccine presentations. 市售冻干呼吸道合胞病毒疫苗的制备时间和可用性评价。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-09-22 DOI: 10.1080/14760584.2025.2559672

Robyn Moucka, Erica Chilson, Brittany Conrad, Sarah Weiser, Simon Moss, Michael Bruchsaler

{"title":"Preparation time and usability assessment of commercially available freeze-dried respiratory syncytial virus vaccine presentations.","authors":"Robyn Moucka, Erica Chilson, Brittany Conrad, Sarah Weiser, Simon Moss, Michael Bruchsaler","doi":"10.1080/14760584.2025.2559672","DOIUrl":"10.1080/14760584.2025.2559672","url":null,"abstract":"Background: This study compared health-care practitioners (HCPs) preparation times, preferences, and perception of usability benefits between two respiratory syncytial virus (RSV) vaccine reconstitution systems.Research design and methods: HCPs with experience reconstituting vaccines prepared two vaccines, the RSVpreF vaccine in a dual chamber vial system (Act-O-Vial; AOV) and the RSVPreF3 vaccine in a vial and vial system (V/V). Following a set of noncommercial instructions, participants completed four timed reconstitution trials with each system. Participants were blinded to systems. After timing trials, feedback was solicited from participants.Results: Sixty participants completed the study. A timing advantage for the AOV was observed for 55 (92%) participants. Mean (SD) reconstitution times were 88 (22) and 119 (39) seconds for the AOV and V/V, respectively. Forty-five (75%) participants preferred the AOV, with 21 preferring it very strongly. AOV was perceived to be less prone for needle sticks (90%) and medication error (90%), faster (87%), and was considered safer (85%) than the V/V. Overall, 82% of participants reported that the AOV fit their workflow better.Conclusions: Compared with the V/V, the AOV was faster, preferred by participants, and reported to have more usability benefits. Findings suggest that AOV will be well accepted by HCPs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"873-881"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany. 德国50岁及以上成人呼吸道合胞病毒预防佐剂RSVPreF3疫苗的公共卫生影响和成本效益

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI: 10.1080/14760584.2025.2539887

Maria Waize, Pavo Marijic, Alen Marijam, Foteini Gkalapi, Elisa Turriani, Franziska Jakobs, Indra Jaidhauser, Dorothea Münch, Sara Pedron, Eleftherios Zarkadoulas

{"title":"Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany.","authors":"Maria Waize, Pavo Marijic, Alen Marijam, Foteini Gkalapi, Elisa Turriani, Franziska Jakobs, Indra Jaidhauser, Dorothea Münch, Sara Pedron, Eleftherios Zarkadoulas","doi":"10.1080/14760584.2025.2539887","DOIUrl":"10.1080/14760584.2025.2539887","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in older adults. Vaccination is effective against RSV disease and can reduce disease and economic burden.Research design and methods: A static, multicohort Markov model was adapted to the German setting to estimate the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination strategies from a societal perspective in three target populations: 1) at increased risk (AIR) adults aged 50-59 years and all adults ≥60 years, 2) all adults aged ≥60 years, and 3) AIR adults aged 60-74 years and all adults ≥75 years. A cycle length of 1 month and a 5-year time horizon were adopted. Vaccine coverage was 75% in the base case.Results: RSV vaccination is cost-effective versus no vaccination (<€50,000 willingness-to-pay threshold): incremental cost-effectiveness ratios were €19,789, €19,631, and €12,733 for strategies 1, 2, and 3, respectively; 1.6, 1.4, and 0.8 million outpatient visits and 192,402, 185,238, and 152,781 hospitalizations could be prevented with strategies 1, 2, and 3, respectively.Conclusions: Expanding RSV vaccination to a larger target population would prevent more RSV cases, though at a higher cost per case averted; all vaccination strategies would be deemed cost-effective in Germany.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"782-796"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0